Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Meta Expands AI Training With Employee Activity Tracking Tools 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
SEATTLE, March 14, 2017 -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that preclinical data for new bispecific antibody candidates targeting CD123 and CD3 will be presented in a poster session at the 2017 Annual Meeting of the American Association for Cancer Research (AACR) to be held in Washington D.C., April 1-5, 2017.
Based on Aptevo’s proprietary ADAPTIR™ protein therapeutic platform, the Company’s latest bispecific candidates targeting CD123 were designed to redirect T-cell cytotoxicity to CD123-expressing tumors cells, a cell surface receptor highly expressed in several hematological malignancies. Results being presented at AACR will examine the in vitro and in vivo activity of optimized lead candidates, APVO436 and APVO437, in preclinical models of acute myeloid leukemia (AML).
| Title: | Bispecific anti-CD123 x anti-CD3 ADAPTIR Molecules for Redirected T-cell Cytotoxicity in Hematological Malignancies |
| Date/Time: | April 2, 2017 – 1:00 – 5:00 pm ET |
| Session Title: | T-Cell Immunity to Cancer – New Progress (Immunology) |
| Abstract ID: | 597/1 |
Abstracts for the AACR annual meeting are available and can be viewed online at www.aacr.org. Aptevo’s poster presentation will be available on the Investor Relations section of the Company’s website at www.aptevotherapeutics.com following the poster session.
About Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. is a biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Our core technology is the ADAPTIR™ (modular protein technology) platform. Aptevo has four commercial products in the areas of hematology and infectious diseases, as well as various investigational stage product candidates in immuno-oncology.
Source: Aptevo Therapeutics Stacey Jurchison Senior Director, Investor Relations and Corporate Communications 206-859-6628 [email protected]
